Advancing Clinical Care and Research with Confidence
care trends across the nation.
Advancing Clinical Care and Research with Confidence
Gain tailored insights into cardiovascular trends across the nation.
The Challenge
Patient Enrollment Is Time Consuming and Costly
egnite provides a more targeted, efficient way to conduct trials and research:
Find the Right Patients
at the Right Time
Using artificial intelligence and advanced data processing to pre-screen for eligible patients
Streamline Enrollment
Improve efficiencies by up to 55% compared to traditional screening techniques
Discover Key Drivers
of Patient Attrition
Enhance patient and site selection
PARTNERS
The Data
Welcome to One of the Largest Ecosystems of Real-World Cardiovascular Data
Longitudinal, echo and EHR data validated by clinicians daily
Leading-edge big data processing techniques scan over 3,000 unique data points per patient, updating data nightly
Proprietary NLP transforms unstructured echo data into usable information
Geographically diverse dataset from across the U.S.
Proprietary NLP transforms unstructured echo data into usable information
Geographically diverse dataset from across the U.S.
Longitudinal, echo and EHR data validated by clinicians daily
Leading-edge big data processing techniques scan over 3,000 unique data points per patient, updating data nightly
*Data from egnite’s de-identified database of 26 teaching and non-teaching US institutions with appropriate permissions.
Our Products
egnite Therapy Accelerator
for existing therapies
for existing therapies
for clinical trials
egnite Research
Collaborate to answer contemporary questions in cardiovascular disease:
Heart
Failure
Atrial
Fibrillation
Mitral
Regurgitation
Mitral
Stenosis
Tricuspid
Regurgitation
Aortic
Regurgitation
Aortic
Stenosis
Presented or Published In
Testimonials
Leading life sciences organizations partner with egnite to expand the boundaries of research and care.
JenaValve
Ancora Heart
Resources
Acute Valve Syndrome in Aortic Stenosis
“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly from intervention before symptoms appear.” […]
egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR) Key Findings Demonstrate 3x Improved Survival for Asymptomatic AS Patients Undergoing AVR versus AS Patients Presenting with Acute Valve Syndrome ALISO VIEJO, Calif. – October 28, 2024 – egnite, Inc., a leading cardiovascular digital health company, today announced the […]
egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference
egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to improve cardiovascular patient care nationwide.